Postherpetic Neuralgia
Conditions
Interventions
DSP group:Inject 20mL of 0.25% ropivacaine combined with 1mL (5mg) of dexamethasone sodium phosphate
DXP group:Injection of 20ml of 0.25% ropivacaine combined with 1ml (5mg) of dexamethasone palmitate injection
Sponsors
The First Affiliated Hospital of Wenzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1 Age >= 18 years; 2 Pain persisting for >= 3 months after rash healing; 3 VAS score >= 4; 4 Voluntarily signed informed consent.
Exclusion criteria
Exclusion criteria: Allergic to dexamethasone or local anesthetics; severe heart, kidney, or liver dysfunction; concomitant mental illness or severe cognitive impairment; pregnancy or breastfeeding; local infection or contraindications to nerve block.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relative decrease in resting VAS on day 7 after treatment (%?VAS7); | — |
Secondary
| Measure | Time frame |
|---|---|
| Onset time of analgesia;Trend of resting VAS changes;Quality of Life (SF-36 Total Score);Sleep Quality (PSQI Total Score);Incidence of adverse reactions; | — |
Countries
China
Contacts
Public ContactHongfei Chen
The First Affiliated Hospital of Wenzhou Medical University
Outcome results
None listed